Knight Therapeutics (KHTRF) has relaunched MYFEMBREE in Canada. In June 2024, Knight and Sumitomo Pharma America announced that Knight and SMPA’s affiliates had entered into exclusive license and supply agreements to commercialize MYFEMBREE, ORGOVYX and vibegron in Canada, as well as an asset purchase agreement under which Knight acquired certain mature products.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics announces normal course issuer bid
- Knight Therapeutics’ Earnings Call Highlights Growth and Expansion
- Knight Therapeutics: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- Knight Therapeutics Reports Record Revenue Amid Net Loss
- Knight Therapeutics Achieves Record Revenues Amid Strategic Expansions